Titan Pharmaceuticals

📍 South San Francisco, United States🗓 Founded 1992👥 32 employees💰 Last funded Jan 2017
Pharmaceutical Manufacturing🌐 titanpharm.com
Website LinkedIn
Titan Pharmaceuticals Inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product is Probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. It was approved by the U.S. Food and Drug Administration in May 2016 and is being commercialized in the U.S. by partner Braeburn Pharmaceuticals. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
1992
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Titan Pharmaceuticals?
Titan Pharmaceuticals has 1 investors on record on gritt.io.
When did Titan Pharmaceuticals last raise funding?
The most recent investment in Titan Pharmaceuticals recorded on gritt.io was in January 2017.
When was Titan Pharmaceuticals founded?
Titan Pharmaceuticals was founded in 1992.
What industry is Titan Pharmaceuticals in?
Titan Pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Titan Pharmaceuticals based?
Titan Pharmaceuticals is headquartered in South San Francisco, United States.